Heart failure remains a major clinical and public health concern and is a major cause of morbidity and mortality globally. Heart failure is characterized by an inability of the heart to supply tissues with enough blood and oxygen to meet their metabolic requirements. Such reduced cardiac function is typically the result of cardiovascular conditions and related changes in structure and function, including myocardial ischemia, valve disease, endocardial, or pericardial abnormalities and arrhythmias. In heart failure there is currently a lack of specific diagnostic biomarkers and therapeutic targets, contributing to the sustained high mortality rates.
After being long considered as non-functional in the human genome, non-coding RNAs have emerged as potential therapeutic targets in recent years. Research has implicated various types of non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), transfer RNAs (tRNAs) and short interfering (siRNAs), in cardiovascular disease processes. Advancements in the understanding of, and technology to investigate non-coding RNAs has led to increasing recognition of the role of non-coding RNAs in heart failure. Non-coding RNAs primarily have a regulatory role in the development of heart failure. They act to regulate post-transcriptional gene expression, either through the inhibition of the translation of mRNA or the induction of the degradation of specific mRNA. An understanding of the role of specific non-coding RNAs in the development of heart failure could allow the development of novel biomarkers and therapeutic targets.
Cardiovascular genetics and systems medicine in Frontiers in Cardiovascular Medicine has developed an article collection on Non-Coding RNAs in Heart Failure to promote the advancement of knowledge in the field. This research topic is devoted to highlighting novel pre-clinical research and clinical studies on the role of non-coding RNAs in heart failure, ranging from molecular mechanisms to diagnosis and prevention and implications for therapeutic approaches.
Potential sub-topics may include but are not limited to:
1) Differences in non-coding RNA profiles between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
2) Non-coding RNAs as biomarkers in heart failure.
3) The role of non-coding RNAs in the pathogenesis of heart failure.
4) The therapeutic potential of non-coding RNAs in heart failure.
Heart failure remains a major clinical and public health concern and is a major cause of morbidity and mortality globally. Heart failure is characterized by an inability of the heart to supply tissues with enough blood and oxygen to meet their metabolic requirements. Such reduced cardiac function is typically the result of cardiovascular conditions and related changes in structure and function, including myocardial ischemia, valve disease, endocardial, or pericardial abnormalities and arrhythmias. In heart failure there is currently a lack of specific diagnostic biomarkers and therapeutic targets, contributing to the sustained high mortality rates.
After being long considered as non-functional in the human genome, non-coding RNAs have emerged as potential therapeutic targets in recent years. Research has implicated various types of non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), transfer RNAs (tRNAs) and short interfering (siRNAs), in cardiovascular disease processes. Advancements in the understanding of, and technology to investigate non-coding RNAs has led to increasing recognition of the role of non-coding RNAs in heart failure. Non-coding RNAs primarily have a regulatory role in the development of heart failure. They act to regulate post-transcriptional gene expression, either through the inhibition of the translation of mRNA or the induction of the degradation of specific mRNA. An understanding of the role of specific non-coding RNAs in the development of heart failure could allow the development of novel biomarkers and therapeutic targets.
Cardiovascular genetics and systems medicine in Frontiers in Cardiovascular Medicine has developed an article collection on Non-Coding RNAs in Heart Failure to promote the advancement of knowledge in the field. This research topic is devoted to highlighting novel pre-clinical research and clinical studies on the role of non-coding RNAs in heart failure, ranging from molecular mechanisms to diagnosis and prevention and implications for therapeutic approaches.
Potential sub-topics may include but are not limited to:
1) Differences in non-coding RNA profiles between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
2) Non-coding RNAs as biomarkers in heart failure.
3) The role of non-coding RNAs in the pathogenesis of heart failure.
4) The therapeutic potential of non-coding RNAs in heart failure.